Compare ARBB & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBB | SKYE |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 9.0M |
| IPO Year | 2022 | 2013 |
| Metric | ARBB | SKYE |
|---|---|---|
| Price | $4.36 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $15.00 |
| AVG Volume (30 Days) | 10.4K | ★ 516.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $0.26 |
| 52 Week High | $13.89 | $4.99 |
| Indicator | ARBB | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 68.24 |
| Support Level | N/A | $0.66 |
| Resistance Level | N/A | $2.32 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 65.57 |
ARB IOT Group Ltd is a provider of complete solutions to the clients for the integration of Internet of Things (IoT) systems and devices from designing to project deployment. The company offers a wide range of IoT systems as well as provides customers with a substantial range of services such as system integration and system support services. It delivers solutions like designing, installation, testing and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company operates in two reportable segments: (i) the provision of hardware and software of IoT solutions and (ii) Investment holding and others. The majority of revenue is generated from the IoT solutions segment.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.